Business
Acadia Pharmaceuticals develops and markets neuroscience medicines.
Acadia Pharmaceuticals grew revenue, remained profitable, generated positive free cash flow at a 9.8% operating margin. Accounting warrants closer review. The Beneish screen flagged and earnings quality was grey; this is a statistical warning, not evidence of misconduct.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 11.9%OK
- Profitability — Net income grew 72.7% to $391M from $226.451MOK
- Cash flow — Free cash flow declined 33.1% to $105.146M from $157.196MWatch
- Margins — Operating margin contracted 1432 bps to 9.78%Watch
- Accounting — Accounting warrants closer reviewWatch
- Insiders — 0 purchases and 20 salesWatch
Where the revenue comes from
Fiscal 2025, as ACADIA PHARMACEUTICALS INC reports it. History and quarterly detail are in the app.
- Nuplazid$680.1M
- Daybue$391.4M
Leadership changes
From ACADIA PHARMACEUTICALS INC's own filings, the day they're filed.
- Elizabeth H. · Directors · departureeff. 2026-04-27
- Z. Thompson · Directors · departureeff. 2026-04-27
- Daniel B. Soland · Directors · departureeff. 2025-10-30
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-05-29
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ACADIA PHARMACEUTICALS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.